X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs TEVA PHARMA (Israel) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-18
TEVA PHARMA
Dec-13
SUN PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs7012,906-   
Low Rs4332,524-   
Sales per share (Unadj.) Rs110.41,667.5-  
Earnings per share (Unadj.) Rs11.0104.2-  
Cash flow per share (Unadj.) Rs17.2239.0-  
Dividends per share (Unadj.) Rs2.0091.19-  
Dividend yield (eoy) %0.43.4 10.5%  
Book value per share (Unadj.) Rs158.81,852.3-  
Shares outstanding (eoy) m2,399.26848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.11.6 315.4%   
Avg P/E ratio x51.626.1 198.1%  
P/CF ratio (eoy) x32.911.4 289.6%  
Price / Book Value ratio x3.61.5 243.6%  
Dividend payout %18.287.5 20.8%   
Avg Mkt Cap Rs m1,360,0212,302,142 59.1%   
No. of employees `00017.844.9 39.6%   
Total wages/salary Rs m53,6710-   
Avg. sales/employee Rs Th14,890.931,462.0 47.3%   
Avg. wages/employee Rs Th3,017.10-   
Avg. net profit/employee Rs Th1,480.61,965.4 75.3%   
INCOME DATA
Net Sales Rs m264,8951,414,058 18.7%  
Other income Rs m8,3880-   
Total revenues Rs m273,2821,414,058 19.3%   
Gross profit Rs m56,081387,240 14.5%  
Depreciation Rs m14,998114,300 13.1%   
Interest Rs m5,17627,774 18.6%   
Profit before tax Rs m44,295245,166 18.1%   
Minority Interest Rs m01,114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-9,505-160,938 5.9%   
Tax Rs m8,452-2,993 -282.4%   
Profit after tax Rs m26,33888,335 29.8%  
Gross profit margin %21.227.4 77.3%  
Effective tax rate %19.1-1.2 -1,562.9%   
Net profit margin %9.96.2 159.2%  
BALANCE SHEET DATA
Current assets Rs m316,359955,049 33.1%   
Current liabilities Rs m198,643832,884 23.9%   
Net working cap to sales %44.48.6 514.4%  
Current ratio x1.61.1 138.9%  
Inventory Days Days9591 104.4%  
Debtors Days Days10896 112.3%  
Net fixed assets Rs m213,178461,862 46.2%   
Share capital Rs m2,3993,481 68.9%   
"Free" reserves Rs m378,6060-   
Net worth Rs m381,0061,570,750 24.3%   
Long term debt Rs m17,721723,039 2.5%   
Total assets Rs m643,0283,231,575 19.9%  
Interest coverage x9.69.8 97.3%   
Debt to equity ratio x00.5 10.1%  
Sales to assets ratio x0.40.4 94.1%   
Return on assets %4.93.6 136.4%  
Return on equity %6.95.6 122.9%  
Return on capital %10.04.9 203.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m10,6730-   
CASH FLOW
From Operations Rs m39,072225,328 17.3%  
From Investments Rs m-33,708-79,843 42.2%  
From Financial Activity Rs m-15,393-270,296 5.7%  
Net Cashflow Rs m-7,359-124,811 5.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 69.61 Rs / USD

Compare SUN PHARMA With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  

Compare SUN PHARMA With: TTK HEALTHCARE  PANACEA BIOTECH  J.B.CHEMICALS  DR. REDDYS LAB  WYETH LTD  



Today's Market

Sensex Ends 66 Points Higher; Realty and Consumer Durable Stocks Witness Buying(Closing)

Indian share markets continued to witness volatility during closing hours and ended their day on a flat note.

Related Views On News

SUN PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 53.4% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, SUN PHARMA has posted a net profit of Rs 7 bn (down 53.4% YoY). Sales on the other hand came in at Rs 72 bn (up 2.7% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

The Great Indian NBFC Bubble Has Burst but I Will Still Recommend These Safe NBFCs(The 5 Minute Wrapup)

Jun 11, 2019

One chart that predicted the NBFC crisis back in 2016.

Just One Stock Made Buffett Billions - And Can Make You Crores(Profit Hunter)

Jun 6, 2019

Coca Cola is arguably one of Warren Buffet's best stock picks. But did you know that small investors picked up the stock five decades before Buffet? Read on...

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why Modi 2.0 Will Be Great for These 7 Stocks(Profit Hunter)

Jun 10, 2019

The government's focus on Infra, electricity, water for all will be the key factors for Sensex 1,00,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Jun 19, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SUN PHARMA 8-QTR ANALYSIS

COMPARE SUN PHARMA WITH

MARKET STATS